Research Reports Gold Mining丨Guosen: Maintain Winner Medical "Outperform the Market" rating, raising the Target Price to 43-47 yuan.

Gelonghui Finance · 14:46

Guosen's Research Reports point out that in the fourth quarter of 2024, Winner Medical (300888.SZ) Consumer Business is expected to achieve accelerated growth against the backdrop of enhanced marketing efforts and the fermentation of industry hot events. Third-party online data shows that from October to November 2024, the combined sales growth rate of the All Cotton Era brand and the Nice Princess brand has significantly accelerated compared to the first three quarters of 2024, with sales growth in the company's two core categories, cotton soft towels and sanitary napkins, exceeding 30% from October to November. In the Medical Sector, the high base effect from epidemic prevention products started to be eliminated in the third quarter, returning to normalized growth. In terms of external growth, the acquisition of GRI is favorable for expanding overseas production capacity and distribution channels. Based on the upward revision of profit forecasts, the Target Price is increased to 43-47 yuan (previously 34-36 yuan), corresponding to a 24-26x PE for 2025, maintaining an 'outperform the market' rating.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

研报掘金丨国信证券：维持稳健医疗“优于大市”评级，上调目标价至43-47元

Research Reports Gold Mining丨Guosen: Maintain Winner Medical "Outperform the Market" rating, raising the Target Price to 43-47 yuan.

Risk Disclaimer

Statement